EMA — authorised 18 February 2019
- Marketing authorisation holder: SHIONOGI B.V.
- Status: approved
🇪🇺 Symproic in European Union
EMA authorised Symproic on 18 February 2019
Marketing authorisations
EMA — authorised 18 February 2019
- Application: EMEA/H/C/004256
- Marketing authorisation holder: Shionogi B.V.
- Local brand name: Rizmoic
- Indication: Rizmoic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.
- Status: approved
Symproic in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in European Union
Frequently asked questions
Is Symproic approved in European Union?
Yes. EMA authorised it on 18 February 2019; EMA authorised it on 18 February 2019.
Who is the marketing authorisation holder for Symproic in European Union?
SHIONOGI B.V. holds the EU marketing authorisation.